PharMerica loses bid to have Supreme Court review 'copycat' lawsuit decision

The U.S. Supreme Court announced Monday that it has declined to review a case that the nation's second largest long-term care pharmacy fears could lead to “me too” lawsuits. The nation's highest court ended its term without moving forward on the company's petition.

As a result, the pharmacy provider faces the prospect of potentially defending itself against multiple False Claims Act lawsuits.

The company's April appeal stemmed from the Supreme Court's May 2015 decision on the FCA's “first-to-file” standard. In it, the justices determined that a lower court's decision to allow simultaneous lawsuits to proceed in a whistleblower case was permissible.